Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

78 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma.
Tam CS, Bassett R, Ledesma C, Korbling M, Alousi A, Hosing C, Kebraei P, Harrell R, Rondon G, Giralt SA, Anderlini P, Popat U, Pro B, Samuels B, Hagemeister F, Medeiros LJ, Champlin RE, Khouri IF. Tam CS, et al. Among authors: ledesma c. Blood. 2009 Apr 30;113(18):4144-52. doi: 10.1182/blood-2008-10-184200. Epub 2009 Jan 23. Blood. 2009. PMID: 19168784 Free PMC article.
Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies.
Kebriaei P, Madden T, Kazerooni R, Wang X, Thall PF, Ledesma C, Nieto Y, Shpall EJ, Hosing C, Qazilbash M, Popat U, Khouri I, Champlin RE, Jones RB, Andersson BS. Kebriaei P, et al. Among authors: ledesma c. Biol Blood Marrow Transplant. 2011 Mar;17(3):412-20. doi: 10.1016/j.bbmt.2010.07.016. Epub 2010 Jul 30. Biol Blood Marrow Transplant. 2011. PMID: 20674757 Free PMC article. Clinical Trial.
Gemcitabine, fludarabine and melphalan as a reduced-intensity conditioning regimen for allogeneic stem cell transplant in relapsed and refractory Hodgkin lymphoma: preliminary results.
Anderlini P, Saliba RM, Ledesma C, Chancoco C, Alousi AM, Shpall EJ, Popat UR, Hosing CM, Khouri IF, Nieto Y, Ciurea S, Younes A, Fanale MA, Acholonu S, Valverde R, Champlin RE. Anderlini P, et al. Among authors: ledesma c. Leuk Lymphoma. 2012 Mar;53(3):499-502. doi: 10.3109/10428194.2011.615427. Epub 2011 Oct 24. Leuk Lymphoma. 2012. PMID: 21859247 Free PMC article. Clinical Trial. No abstract available.
Donor leukocyte infusions in recurrent Hodgkin lymphoma following allogeneic stem cell transplant: 10-year experience at the M. D. Anderson Cancer Center.
Anderlini P, Saliba R, Acholonu S, Okoroji GJ, Ledesma C, Andersson BS, Jones R, Popat UR, Hosing CM, Nieto Y, Qazilbash MH, Ueno NT, Giralt SA, de Lima MJ, Champlin RE. Anderlini P, et al. Among authors: ledesma c. Leuk Lymphoma. 2012 Jun;53(6):1239-41. doi: 10.3109/10428194.2011.644547. Epub 2012 Jan 5. Leuk Lymphoma. 2012. PMID: 22132837 Free PMC article. No abstract available.
Intravenous BU plus Mel: an effective, chemotherapy-only transplant conditioning regimen in patients with ALL.
Kebriaei P, Madden T, Wang X, Thall PF, Ledesma C, de Lima M, Shpall EJ, Hosing C, Qazilbash M, Popat U, Alousi A, Nieto Y, Champlin RE, Jones RB, Andersson BS. Kebriaei P, et al. Among authors: ledesma c. Bone Marrow Transplant. 2013 Jan;48(1):26-31. doi: 10.1038/bmt.2012.114. Epub 2012 Jun 25. Bone Marrow Transplant. 2013. PMID: 22732703 Free PMC article. Clinical Trial.
Clofarabine combined with busulfan provides excellent disease control in adult patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation.
Kebriaei P, Basset R, Ledesma C, Ciurea S, Parmar S, Shpall EJ, Hosing C, Khouri I, Qazilbash M, Popat U, Alousi A, Nieto Y, Jones RB, de Lima M, Champlin RE, Andersson BS. Kebriaei P, et al. Among authors: ledesma c. Biol Blood Marrow Transplant. 2012 Dec;18(12):1819-26. doi: 10.1016/j.bbmt.2012.06.010. Epub 2012 Jun 29. Biol Blood Marrow Transplant. 2012. PMID: 22750645 Free PMC article. Clinical Trial.
Outcomes of adults with acute lymphoblastic leukemia relapsing after allogeneic hematopoietic stem cell transplantation.
Poon LM, Hamdi A, Saliba R, Rondon G, Ledesma C, Kendrick M, Qazilbash M, Hosing C, Jones RB, Popat UR, Nieto Y, Alousi A, Ciurea S, Shpall EJ, Champlin RE, Kebriaei P. Poon LM, et al. Among authors: ledesma c. Biol Blood Marrow Transplant. 2013 Jul;19(7):1059-64. doi: 10.1016/j.bbmt.2013.04.014. Epub 2013 Apr 30. Biol Blood Marrow Transplant. 2013. PMID: 23644077 Free PMC article.
Comparison of outcomes at two institutions of patients with ALL receiving ex vivo T-cell-depleted or unmodified allografts.
Hobbs GS, Hamdi A, Hilden PD, Goldberg JD, Poon ML, Ledesma C, Devlin SM, Rondon G, Papadopoulos EB, Jakubowski AA, O'Reilly RJ, Champlin RE, Giralt S, Perales MA, Kebriaei P. Hobbs GS, et al. Among authors: ledesma c. Bone Marrow Transplant. 2015 Apr;50(4):493-8. doi: 10.1038/bmt.2014.302. Epub 2015 Jan 26. Bone Marrow Transplant. 2015. PMID: 25621808 Free PMC article. Clinical Trial.
78 results